Abstract: The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probiotic Escherichia coli strain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopetide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

Abstract: The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probiotic Escherichia coli strain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopeptide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

Abstract: The present invention relates to compound of formula (I): wherein R is O—R3 or R1 and R2 are identical or different and are each independently H, (C1-C6)alkyl, —CO—(C1-C21)alkyl or —CO—(C11-C21)alkenyl group, provided that at least one of R1 or R2 is H or (C1-C6)alkyl, R3 is a —CO—(C11-C21)alkyl or —CO—(C11-C21)alkenyl group, or its pharmaceutically acceptable salts, racemates, diastereoisomers, enantiomers, or mixtures thereof, for use in prevention and/or treatment of a disease or disorder linked to an exacerbated vascular, lymphatic or mucosal permeability.

Abstract: The present invention relates to a compound of formula (I) wherein: i is 0 or 1; j is 0 or 1; k is 0 or 1; R1 and R2 are in particular H, (C1-C12)alkyl, or a group of formula C(O)R; R is a, linear or branched, alkyl radical, comprising at least 19 carbon atoms; R3 is H and k=0 when j=1; or, when j=0, R3 is —C(O)R or -L-C(O)R; L, U and L? are linkers; wherein, when j=0, at least one of the groups R1; R2 and R3 comprises a radical R.

Abstract: The invention relates to compound of formula (I): in particular flavonoid derivatives (quercetin and catechin derivatives), for use in the prevention and/or the treatment of a disease or disorder involving both carbonyl and oxidative stresses.

Abstract: The present invention relates to compound of formula (I): wherein R is O—R3 or R1 and R2 are identical or different and are each independently H, (C1-C6)alkyl, —CO—(C1-C21)alkyl or —CO—(C11-C21)alkenyl group, provided that at least one of R1 or R2 is H or (C1-C6)alkyl, R3 is a —CO—(C11-C21)alkyl or —CO—(C11-C21)alkenyl group, or its pharmaceutically acceptable salts, racemates, diastereoisomers, enantiomers, or mixtures thereof, for use in prevention and/or treatment of a disease or disorder linked to an exacerbated vascular, lymphatic or mucosal permeability.

Abstract: The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probiotic Escherichia coli strain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopetide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

Abstract: The invention relates to a compound of the general formula (I) N3O2S—Ar-L-Ar?—SO2N3, wherein: —Ar and Ar? are aromatic building blocks; and —L is a linking group comprising at least one heteroatom as well as an organic chain denoted as Sp? and having at least two carbon atoms. The invention also relates to a compound of the general formula (II) wherein: —Ar and Ar? are aromatic building blocks; —L is a covalent bond or a linking group; —m and n are both 0 or 1, at least one of m and n being 1; —Sp and Sp? are organic chains having at least two carbon atoms. The invention also relates to the use of these compounds as cross linking agents in the manufacture of polymers.

Abstract: The present invention relates to a compound of formula (I) wherein:—i is 0 or 1; j is 0 or 1; k is 0 or 1;—R1 and R2 are in particular H, (C1-C12)alkyl, or a group of formula C(O)R;—R is a, linear or branched, alkyl radical, comprising at least 19 carbon atoms;—R3 is H and k=0 when j=1; or, when j=0, R3 is —C(O)R or -L-C(O)R;—L, U and L? are linkers; wherein, when j=0, at least one of the groups R1; R2 and R3 comprises a radical R.

Abstract: The present invention relates to a compound of formula (I) wherein: i is 0 or 1; j is 0 or 1; k is 0 or 1; R1 and R2 are in particular H, (C1-C12)alkyl, or a group of formula C(O)R; R is a, linear or branched, alkyl radical, comprising at least 19 carbon atoms; R3 is H and k=0 when j=1; or, when j=0, R3 is —C(O)R or -L-C(O)R; L, U and L? are linkers; wherein, when j=0, at least one of the groups R1; R2 and R3 comprises a radical R.

Abstract: The invention relates to a compound of the general formula (I) N3O2S—Ar-L-Ar?—SO2N3, wherein: —Ar and Ar? are aromatic building blocks; and —L is a linking group comprising at least one heteroatom as well as an organic chain denoted as Sp? and having at least two carbon atoms. The invention also relates to a compound of the general formula (II) wherein: —Ar and Ar? are aromatic building blocks; —L is a covalent bond or a linking group; —m and n are both 0 or 1, at least one of m and n being 1; —Sp and Sp? are organic chains having at least two carbon atoms.

Abstract: The present invention relates to a compound of formula (I) wherein: —i is 0 or 1; j is 0 or 1; k is 0 or 1; —R1 and R2 are in particular H, (C1-C12)alkyl, or a group of formula C(O)R; —R is a, linear or branched, alkyl radical, comprising at least 19 carbon atoms; —R3 is H and k=0 when j=1; or, when j=0, R3 is —C(O)R or -L-C(O)R; —L, U and L? are linkers; wherein, when j=0, at least one of the groups R1; R2 and R3 comprises a radical R.

Abstract: A method for preparing 2-(n-butyl)-5-nitrobenzofuran from 1-halo-4-nitrobenzene, characterized in that 1-hexen-3-ol is reacted, and then the product is subject to a Claisen rearrangement, followed by catalytic intramolecular cyclization.

Abstract: The invention concerns a novel method for preparing vitamin E. More particularly, it concerns a novel method for the condensation of trimethylhydroquinone and isophytol.

Abstract: The invention concerns a novel method for preparing vitamin E. More particularly, it concerns a novel method for the condensation of Arimethylhydroquinone and isophytol.

Abstract: The present invention relates to a process for preparing 9-deoxo-9(Z)-hydroxyiminoerythromycin A corresponding to formula (I) below: from 9-deoxo-9(E)-hydroxyiminoerythromycin A by reaction with a base in water or in a mixture of water/solvent of dialkyl ketone type capable of forming a crystallizable solvate with the desired 9(Z)-oxime; acidification of the reaction mixture to a pH of between 9 and 11; addition to the said mixture of an organic solvent; optionally concentration under vacuum of the resulting organic phase; and isolation of the desired 9(Z)-erythromycin oxime.

Abstract: The invention concerns a novel method for preparing vitamin E. More particularly, it concerns a novel method for the condensation of Arimethylhydroquinone and isophytol.

Abstract: The present invention relates to a process for preparing 9-deoxo-9(Z)-hydroxyiminoerythromycin A corresponding to formula (I) below: 1

Abstract: A method for the preparation of a lactam compound of formula ##STR1## wherein R'.sub.1 and R".sub.1 independently are acyl or aroyl, or taken together form an optionally substituted methylene, and G.sub.1 is hydrogen or an amino protecting group, comprising oxidizing a bis O-protected 1R-2-azadihydroxybicyclo-?2.2.1!heptane compound of formula ##STR2## with about 0.1 mol % to about 1 mol % of RuO.sub.2 or hydrate thereof in the presence of about 3 equivalents of an oxidant to form the lactam compound with an enantiomeric excess of greater than or equal to about 95%.

Abstract: A compound of formula ##STR1## wherein R is a group of formula ##STR2## R.sub.1 is alkyl; and Ar is optionally substituted aryl.